insights_auto
Por que 6160 subiu 4,36%?
Saiba maischevron_right
6160:HKG
BeOne Medicines AG
HK$ 225,00
arrow_upward
+4,36%(+9,40) 1D
16 de out., 16:08:14 GMT+8 · HKD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 6160…
Abrir
HK$ 224,80
Alta
HK$ 230,20
Baixa
HK$ 221,80
Valor de mercado
355,76 bi
Volume médio
2,93 mi
Volume
4,41 mi
Índice P/L
65,67
Alto — 52 sem
HK$ 235,60
Baixo — 52 sem
HK$ 153,00
LPA
HK$ 3,43
Ações em circulação
1,43 bi
Nº de funcionários
12 mil
Abrir
HK$ 224,80
Alta
HK$ 230,20
Baixa
HK$ 221,80
Valor de mercado
355,76 bi
Volume médio
2,93 mi
Volume
4,41 mi
Índice P/L
65,67
Alto — 52 sem
HK$ 235,60
Baixo — 52 sem
HK$ 153,00
LPA
HK$ 3,43
Ações em circulação
1,43 bi
Nº de funcionários
12 mil
Notícias
De fontes da web e parceiros de notícias
ad-hoc-news.de
·
há 23 horas
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Perfil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Sobre BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Funcionários12 mil
Data de fundação28 de out. de 2010
Sede-
Setor-